Evidence map›Paper›PMID 34307391›Full record

ArticleFrontiers in medicine2021

How to Synchronize Longitudinal Patient Data With the Underlying Disease Progression: A Pilot Study Using the Biomarker CRP for Timing COVID-19.

Martina A Maibach, Ahmed Allam, Matthias P Hilty, Nicolas A Perez Gonzalez, Philipp K Buehler, Pedro D Wendel Garcia, Silvio D Brugger, Christoph C Ganter, CoViD-19 ICU-Research Group Zurich, RISC-19-ICU Investigators and 3 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Martina A MaibachInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
Ahmed AllamDepartment of Quantitative Biomedicine, University and University Hospital Zurich, Zurich, Switzerland.
Matthias P HiltyInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
Nicolas A Perez GonzalezDepartment of Quantitative Biomedicine, University and University Hospital Zurich, Zurich, Switzerland.
Philipp K BuehlerInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
Pedro D Wendel GarciaInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
Silvio D BruggerDepartment of Infectious Diseases and Hospital Epidemiology, University and University Hospital Zurich, Zurich, Switzerland.
Christoph C GanterInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
CoViD-19 ICU-Research Group Zurich
RISC-19-ICU Investigators
Michael KrauthammerDepartment of Quantitative Biomedicine, University and University Hospital Zurich, Zurich, Switzerland.
Reto A SchuepbachInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.
Jan BartussekInstitute for Intensive Care Medicine, University and University Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continued digitalization of medicine has led to an increased availability of longitudinal patient data that allows the investigation of novel and known diseases in unprecedented detail. However, to accurately describe any underlying pathophysiology and allow inter-patient comparisons, individual patient trajectories have to be synchronized based on temporal markers. In this pilot study, we use longitudinal data from critically ill ICU COVID-19 patients to compare the commonly used alignment markers "onset of symptoms," "hospital admission," and "ICU admission" with a novel objective method based on the peak value of the inflammatory marker C-reactive protein (CRP). By applying our CRP-based method to align the progression of neutrophils and lymphocytes, we were able to define a pathophysiological window that improved mortality risk stratification in our COVID-19 patient cohort. Our data highlights that proper synchronization of longitudinal patient data is crucial for accurate interpatient comparisons and the definition of relevant subgroups. The use of objective temporal disease markers will facilitate both translational research efforts and multicenter trials.

Indexed as

biomarkerCOVID-19digitalizationlongitudinal datapatient trajectoriesrisk stratificationsubgroup comparisonsynchronization

Identifiers

PMID34307391
PMCPMC8295502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.